白附片对正常和肾阳虚证大鼠毒性反应的比较研究
|
摘要
目的
观察白附片对正常大鼠和肾阳虚证大鼠的毒性反应差异,探索基于中医证候动物模型评价中药毒性的科学、合理性。
方法
建立肾阳虚证大鼠模型,从生化、免疫、病理、代谢组学等方面评价白附片对正常大鼠和肾阳虚证大鼠的毒性反应并比较两者差异。
1.动物
SPF级雄性SD大鼠80只,体重200±20g。
2.分组、造模及给药
80只大鼠随机分为正常组和模型组。模型组连续9d肌注氢化可的松琥珀酸钠溶液35.715 mg/kg·d,制作肾阳虚证模型。造模结束后将两组大鼠分别随机分为低剂量、小剂量、中剂量和大剂量4个给药组和空白对照组,每组8只;给药浓度从低到高依次为:0.32 g/kg·d、0.64 g/kg·d、1.28g/kg·d和2.56 g/kg·d,连续给药14d。
3.取血和取材
给药结束后麻醉取血,制备血清、血浆;取脏器(心、肝、肾、肾上腺、脾);称取脏器湿重、计算脏器系数,4%的甲醛溶液固定组织,以及制备心肌组织匀浆。
4.常规实验研究
4.1观察指标
观察大鼠行为形态及体重的变化。
以Biopac MP多道生理记录仪描记Ⅱ导联心电图,记录心率(BPM)和峰-峰值(p-p),以及心律失常情况。
全血检测:白细胞总数(WBC)、红细胞总数(RBC)、血红蛋白(HGB)和血小板总数(PLT)。
血清生化检测:总胆固醇(CHO)、甘油三酯(TG)、总蛋白(TP)、血糖(GLU)、总胆红素(T-BIL)、尿素氮(BUN)、肌酐(CRE)、γ-谷氨酰转肽酶(GGT)、尿酸(UAC)、天门冬氨酸转换酶(AST)、丙氨酸氨基转换酶(ALT)、肌酸激酶(CK)和乳酸脱氢酶(LDH)。
放射性免疫检测:促肾上腺皮质激素(ACTH),皮质醇(COR),环磷酸腺苷(cAMP)和环磷酸鸟苷(cGMP)。
免疫比浊检测:心肌琥珀酸脱氢酶(SDH)和心肌钠-钾ATP酶(Na~+-k~+-ATPase)。
HE染色,光镜观察心、肝、肾、肾上腺和脾脏的病理改变情况。
4.2统计分析
计量资料采用单因素方差分析,广义线性模型两因素方差分析、协方差分析、球形检验、重复测量方差分析,以及直线回归分析;计数资料用Logistic回归分析。显著性水平取P<0.05。
5.代谢组学研究
采用液相色谱-质谱联用的代谢组学技术获取代谢物指纹图谱数据;用正交偏最小二乘法对数据进行挖掘。
结果
1.常规实验研究结果
1.1大鼠行为形态及体重变化情况
随着给药剂量的增大,正常大鼠的行为形态毒性表现比模型大鼠突出;在低剂量给药时,模型大鼠肾阳虚表现明显缓解,白附片发挥治疗效应。正常和模型大鼠体重均随天数增长,剂量越大增长的幅度越小,提示白附片的毒性与剂量相关,剂量越大则毒性越大;在低剂量给药时,模型大鼠体重随天数增长的幅度较正常大鼠大,白附片发挥治疗效应。
1.2主要血常规指标变化情况
氢化可的松造模导致WBC和PLT降低。给白附片后,正常大鼠WBC和PLT随剂量增加而降低,表现为白附片的毒性效应;而模型大鼠WBC和PLT随剂量增加而升高,表现为白附片的治疗效应。氢化可的松造模可导致RBC和HGB的降低,尤其以HGB降低更为明显。白附片对正常大鼠的RBC和HGB有一定的影响,主要表现为随着剂量的增加RBC和HGB有轻微降低的趋势。对模型大鼠,低剂量白附片能提高血液RBC和HGB的水平。
1.3血清糖、脂、蛋白指标变化情况
氢化可的松造模导致GLU降低。给白附片后,正常大鼠GLU随剂量增加而降低,表现为白附片对正常大鼠的毒性效应;而模型大鼠GLU随剂量增加而升高并趋于正常,表现为白附片提高正常大鼠GLU的治疗效应。氢化可的松造模导致TG的升高,而给白附片后,模型大鼠TG有降低的趋势。给予白附片能使正常大鼠和模型大鼠CHO和TP有升高的趋势。
1.4反映心脏功能的指标变化情况
白附片可使正常大鼠和模型大鼠心律失常。随着剂量的增加,心律失常发生率升高。白附片引起模型大鼠心律失常的发生率低于同剂量白附片引起正常大鼠心律失常的发生率,提示白附片对正常大鼠的心律影响更大。白附片可加快正常大鼠和模型大鼠的心率,随着剂量的增加心率加快,但模型大鼠心率加快的幅度较小。白附片引起正常大鼠和模型大鼠P-P增大,增幅一致。
随着白附片剂量的增大,正常大鼠和模型大鼠的心脏系数和LDH有增大的趋势。正常大鼠LDH升高的更快,反映了白附片对正常大鼠周围心肌酶的异常影响。随着白附片剂量的增加,正常大鼠和模型大鼠的SDH和Na~+-K~+-ATP酶有下降的趋势,正常大鼠SDH下降的更快,提示白附片也对正常大鼠和模型大鼠的心肌组织线粒体标志酶有不同的影响。
1.5反映肝肾功能的指标变化情况
随着白附片剂量的增加,正常大鼠和模型大鼠的ALT有升高的趋势,正常大鼠升高的更快,提示白附片对正常大鼠的肝毒性更突出。随着白附片剂量的增加,正常大鼠BUN有升高的趋势,反映了白附片可能对正常大鼠有一定的肾毒性。
1.6反映神经、内分泌功能的指标变化情况
氢化可的松造模导致cAMP和COR降低而cGMP升高。随着白附片剂量增加,模型大鼠cAMP/cGMP和COR有升高的趋势。随着白附片剂量的增加,正常大鼠和模型大鼠的肾上腺系数有增大的趋势,而胸腺系数有减小的趋势。
1.7病理组织形态学变化情况
白附片可引起正常大鼠和模型大鼠心、肝、肾、肾上腺和脾脏的组织形态学改变,其改变程度随着剂量的增加而加重。同一剂量给药时,两种大鼠同一脏器的病理改变存在差异,模型大鼠病理改变相对较轻。
2.代谢组学研究结果
氢化可的松造模导致溶血磷脂酰乙醇胺(18:0LPE)和溶血磷脂酰胆碱(20:5LPC)下调。18:0LPE和20:5LPC是正常大鼠和模型大鼠给予白附片后两者血浆代谢不同变化的主要标志物。正常大鼠18:0LPE和20:5LPC随剂量的增加有下降的趋势,而模型大鼠变化不明显。
结论
本研究发现:白附片可导致正常大鼠和肾阳虚大鼠行为形态,体重,血细胞,糖、脂、蛋白代谢,心、肝、肾功能,神经、内分泌功能,组织形态学,以及血浆代谢物的异常。这些异常反映了白附片对正常大鼠和肾阳虚大鼠的毒性作用。两者异常的差异表现为所涉及的指标不同,并且同一指标的异常程度有差异,具体可见白附片导致肾阳虚大鼠的异常指标相对较少,异常程度较轻。而且,从某些指标来看,白附片对肾阳虚大鼠有明显的治疗作用。本研究为基于中医证候动物模型评价中药毒性的合理性提供了客观依据,是丰富和完善现代药物毒性评价理论和方法体系的有益探索。
Objective
To observe the difference of Toxic Reaction of white prepared lateral root to normal and kidney yang deficiency rats and explore the rationality of evaluating the toxicity of traditional Chinese herbs based upon traditional Chinese medicine(TCM) syndrome animal model.
Methods
Eighty Sprague-Dawley(SD) male rats were divided randomly into normal and kidney yang deficient model group,forty rats respectively.After producing kidney yang deficient model to rats in model group by injecting hydrocortisoni natrii succinas in intramuscular, normal and model rats were respectively and randomly divided into low,little,medium,great dose group and blank group,eight rats in each group.Those rats were administered orally with different concentrations of white prepared lateral root of aconite every day for two weeks. Taking blood and preparing serum and plasma after anaesthetizating rats.Taking the internal organs(heart,liver,kidney,adrenal gland and spleen),weighing wet heavy and calculating organs coefficient.Fixing the organ with 4%formaldehyde solution,as well as preparing the cardiac muscle organ admixture liquid.
1.The Convention Experiment Study
1.1 Observed Target
Observing the change of rats action,weight and morphology.
TracingⅡcouplet electrocardiogram with Biopac multiple tracks physiology apparatus and recording heart rate(BPM) and peak-to-peak(P-P) as well as arrhythmia.
Blood test:White blood cell total(WBC),red blood cell total(RBC),hemoglobin (HGB) and platelet total(PLT).
Serum biochemistry test:Cholesterol(CHO),total glycerine esters(TG),total protein (TP),glucose(GLU),total bilirubin(T-BIL),urea nitrogen(BUN),urine creatinine(CRE), gamma glutamyl transferase(GGT),uric acid(UAC),glutamic oxaloacetic transaminase (AST),alanine aminotransferase(ALT),creatine Kinase(CK) and lactate dehydrogenase(LDH).
Radioactivity immunity test:Adrenocorticotrophic hormone(ACTH),hydrocortisone (COR),cyclic adenosine monophosphate(cAMP),cyclic guanosine monophosphate(cGMP).
Immunoturbidimetry test:Cardiac muscle Succinate dehydrogenase(SDH) and Na~+-k~+-ATPase enzyme(Na~+-k~+-ATPase).
Dyeing with HE and observing the pathological change of heart,liver,kidney,adrenal gland and spleen with optical microscope.
1.2 Statistical analysis
Quantitative data:adopting one factor analysis of variance,general linear model two factors analysis of variance,covariance analysis,repeated measurement analysis,as well as the straight line regression analysis.Count data:Logistic's regression analysis.P<0.05 was taken to the significance standard.
2.Metabolomics study
Capturing metabolite fingerprint data with the liquid phase color spectrum-mass spectra (LC/MS) metabolomics technology and excavating data orthogonal partial least squares (OPLS).
Results
1.The Convention Experiment Results
1.1 Rats Action,Weight and Morphology Change
As concentration increased,the Toxic Reaction due to action and morphology change of normal rats was more and more evident than model rats'.With low dose of administration, kidney yang deficient syndrome was clearly relieved.The weight of normal and model rats increased with extending time of medication.More dosage accompanied with slighter increase of weight.White prepared lateral root of aconite shown reating effect at low dosage.
1.2 Major Blood Convention Target
Hydrogenation cortisone caused WBC and PLT reduction.After taking white prepared lateral root of aconite,normal rats'WBC and PLT reduced with adding dose,which showed the toxicity effect of white prepared lateral root of aconite.However,model rats'WBC and PLT increased with adding dose,which showed the treating effect of white prepared lateral root of aconite.Hydrogenation cortisone leaded RBC and HGB to reduce,especially HGB reduce much more clearly.White prepared lateral root of aconite had definite influence on normal rats.Mostly representation was that RBC and HGB had the trend of light reduction with adding dose.As to model rats,low dose white prepared lateral root of aconite could raise blood RBC and HGB level.
1.3 Serum Glucose,Ester and Protein Level
Hydrogenation cortisone caused GLU reduce.After taking white prepared lateral root of aconite,normal rats' GLU reduced with adding dose,which showed the toxicity effect of white prepared lateral root of aconite.However,model rats' GLU increased with adding dose, which showed the treating effect of white prepared lateral root of aconite.Hydrogenation cortisone leaded TG to go up.Taking medicine made model rats' TG have a trend of reduction with adding dose.Moreover,taking white prepared lateral root of aconite could make normal rats' CHO and TP go up.
1.4 Heart Function
White prepared lateral root of aconite could cause normal rats and model rats arrhythmia. With the increase of dosage,the occurring rate of arrhythmia went up.The occurring rate of arrhythmia of model rats is lower than normal rats',which pointed out that white prepared lateral root of aconite had more great infaust influence on normal rats.White prepared lateral root of aconite could quicken heart rate and P-P vaule of rats,and both were inclined to quicken with adding dose.The increasing extent of heart rate of model rats was lower than normal rats',but it's the increasing extent of P-P vaule was consistent to normal rats'.
With adding dose,all rats heart coefficient and LDH squinted towards going up.Normal rats'LDH going up was quicker than model rats',which indicated abnormal influence on surrounding cardiac muscle enzyme.With adding dose,all rats SDH and Na~+-K~+-ATPase had a trend of descending.Normal rats' SDH descending was quicker than model rats',which showed white prepared lateral root of aconite also impacted rats'cardiac muscle mitochondrion enzyme.
1.5 Liver and Kidney Function
With adding dose,all rats ALT squinted towards going up,but ALT of normal rats went up more quickly than model rats,which suggested white prepared lateral root of aconite caused more liver toxicity to normal rats.In addition,white prepared lateral root of aconite also produced kidney toxicity to normal rats.
1.6 Nerve and Endocrine Function
Hydrogenation cortisone caused cAMP and COR descend,cGMP increase.With adding dose,cAMP/cGMP and COR of normal rats inceased,both adrenal gland coefficient auxed, but chest gland coefficient descend.
1.7 Morphology Change of Pathology Organ
White prepared lateral root of aconite caused both rats organ morphology change in heart, liver,kidney,adrenal gland and spleen.Trauma extent became serious gradually with adding dose.To same internal organ and same dose medicine,the pathology change of model rats was slighter than normal rats.
2.Metabolomics Study Result
Metabolomics study indicated that Lysophosphatidyl choline(LPC) and lysophosphatidyl ethanolamine(LPE) were chief material symbols among various metabolite in normal and model rats caused by white prepared lateral root of aconite.LPC and LPE had different change trend between normal and model rats with dose change.
Conclusion
This study showed that white prepared lateral root of aconite could cause abnormity in normal rats and kidney yang deficiency rats as following:action and morphology,weight, major blood convention target,serum glucose,serum lipid and protein level,heart function, liver and kidney function,nerve and endocrine function,pathology organ change,and plasma metabolite change.All abnormal changes reflected toxicity effect of white prepared lateral root of aconite to normal and kidney yang deficiency rats.The abnormal targets in kidney yang deficiency model rats were less than in normal rats both in quantity and degree. Moreover,white prepared lateral root of aconite shown treating effect to model rats by some abnormal targets.This study provided objective evidence for the theory of evaluating traditional Chinese herbs toxicity based on TCM syndrome animal model,which proved to be a beneficail exploration in enriching modern medicine toxicity evaluation system.
观察白附片对正常大鼠和肾阳虚证大鼠的毒性反应差异,探索基于中医证候动物模型评价中药毒性的科学、合理性。
方法
建立肾阳虚证大鼠模型,从生化、免疫、病理、代谢组学等方面评价白附片对正常大鼠和肾阳虚证大鼠的毒性反应并比较两者差异。
1.动物
SPF级雄性SD大鼠80只,体重200±20g。
2.分组、造模及给药
80只大鼠随机分为正常组和模型组。模型组连续9d肌注氢化可的松琥珀酸钠溶液35.715 mg/kg·d,制作肾阳虚证模型。造模结束后将两组大鼠分别随机分为低剂量、小剂量、中剂量和大剂量4个给药组和空白对照组,每组8只;给药浓度从低到高依次为:0.32 g/kg·d、0.64 g/kg·d、1.28g/kg·d和2.56 g/kg·d,连续给药14d。
3.取血和取材
给药结束后麻醉取血,制备血清、血浆;取脏器(心、肝、肾、肾上腺、脾);称取脏器湿重、计算脏器系数,4%的甲醛溶液固定组织,以及制备心肌组织匀浆。
4.常规实验研究
4.1观察指标
观察大鼠行为形态及体重的变化。
以Biopac MP多道生理记录仪描记Ⅱ导联心电图,记录心率(BPM)和峰-峰值(p-p),以及心律失常情况。
全血检测:白细胞总数(WBC)、红细胞总数(RBC)、血红蛋白(HGB)和血小板总数(PLT)。
血清生化检测:总胆固醇(CHO)、甘油三酯(TG)、总蛋白(TP)、血糖(GLU)、总胆红素(T-BIL)、尿素氮(BUN)、肌酐(CRE)、γ-谷氨酰转肽酶(GGT)、尿酸(UAC)、天门冬氨酸转换酶(AST)、丙氨酸氨基转换酶(ALT)、肌酸激酶(CK)和乳酸脱氢酶(LDH)。
放射性免疫检测:促肾上腺皮质激素(ACTH),皮质醇(COR),环磷酸腺苷(cAMP)和环磷酸鸟苷(cGMP)。
免疫比浊检测:心肌琥珀酸脱氢酶(SDH)和心肌钠-钾ATP酶(Na~+-k~+-ATPase)。
HE染色,光镜观察心、肝、肾、肾上腺和脾脏的病理改变情况。
4.2统计分析
计量资料采用单因素方差分析,广义线性模型两因素方差分析、协方差分析、球形检验、重复测量方差分析,以及直线回归分析;计数资料用Logistic回归分析。显著性水平取P<0.05。
5.代谢组学研究
采用液相色谱-质谱联用的代谢组学技术获取代谢物指纹图谱数据;用正交偏最小二乘法对数据进行挖掘。
结果
1.常规实验研究结果
1.1大鼠行为形态及体重变化情况
随着给药剂量的增大,正常大鼠的行为形态毒性表现比模型大鼠突出;在低剂量给药时,模型大鼠肾阳虚表现明显缓解,白附片发挥治疗效应。正常和模型大鼠体重均随天数增长,剂量越大增长的幅度越小,提示白附片的毒性与剂量相关,剂量越大则毒性越大;在低剂量给药时,模型大鼠体重随天数增长的幅度较正常大鼠大,白附片发挥治疗效应。
1.2主要血常规指标变化情况
氢化可的松造模导致WBC和PLT降低。给白附片后,正常大鼠WBC和PLT随剂量增加而降低,表现为白附片的毒性效应;而模型大鼠WBC和PLT随剂量增加而升高,表现为白附片的治疗效应。氢化可的松造模可导致RBC和HGB的降低,尤其以HGB降低更为明显。白附片对正常大鼠的RBC和HGB有一定的影响,主要表现为随着剂量的增加RBC和HGB有轻微降低的趋势。对模型大鼠,低剂量白附片能提高血液RBC和HGB的水平。
1.3血清糖、脂、蛋白指标变化情况
氢化可的松造模导致GLU降低。给白附片后,正常大鼠GLU随剂量增加而降低,表现为白附片对正常大鼠的毒性效应;而模型大鼠GLU随剂量增加而升高并趋于正常,表现为白附片提高正常大鼠GLU的治疗效应。氢化可的松造模导致TG的升高,而给白附片后,模型大鼠TG有降低的趋势。给予白附片能使正常大鼠和模型大鼠CHO和TP有升高的趋势。
1.4反映心脏功能的指标变化情况
白附片可使正常大鼠和模型大鼠心律失常。随着剂量的增加,心律失常发生率升高。白附片引起模型大鼠心律失常的发生率低于同剂量白附片引起正常大鼠心律失常的发生率,提示白附片对正常大鼠的心律影响更大。白附片可加快正常大鼠和模型大鼠的心率,随着剂量的增加心率加快,但模型大鼠心率加快的幅度较小。白附片引起正常大鼠和模型大鼠P-P增大,增幅一致。
随着白附片剂量的增大,正常大鼠和模型大鼠的心脏系数和LDH有增大的趋势。正常大鼠LDH升高的更快,反映了白附片对正常大鼠周围心肌酶的异常影响。随着白附片剂量的增加,正常大鼠和模型大鼠的SDH和Na~+-K~+-ATP酶有下降的趋势,正常大鼠SDH下降的更快,提示白附片也对正常大鼠和模型大鼠的心肌组织线粒体标志酶有不同的影响。
1.5反映肝肾功能的指标变化情况
随着白附片剂量的增加,正常大鼠和模型大鼠的ALT有升高的趋势,正常大鼠升高的更快,提示白附片对正常大鼠的肝毒性更突出。随着白附片剂量的增加,正常大鼠BUN有升高的趋势,反映了白附片可能对正常大鼠有一定的肾毒性。
1.6反映神经、内分泌功能的指标变化情况
氢化可的松造模导致cAMP和COR降低而cGMP升高。随着白附片剂量增加,模型大鼠cAMP/cGMP和COR有升高的趋势。随着白附片剂量的增加,正常大鼠和模型大鼠的肾上腺系数有增大的趋势,而胸腺系数有减小的趋势。
1.7病理组织形态学变化情况
白附片可引起正常大鼠和模型大鼠心、肝、肾、肾上腺和脾脏的组织形态学改变,其改变程度随着剂量的增加而加重。同一剂量给药时,两种大鼠同一脏器的病理改变存在差异,模型大鼠病理改变相对较轻。
2.代谢组学研究结果
氢化可的松造模导致溶血磷脂酰乙醇胺(18:0LPE)和溶血磷脂酰胆碱(20:5LPC)下调。18:0LPE和20:5LPC是正常大鼠和模型大鼠给予白附片后两者血浆代谢不同变化的主要标志物。正常大鼠18:0LPE和20:5LPC随剂量的增加有下降的趋势,而模型大鼠变化不明显。
结论
本研究发现:白附片可导致正常大鼠和肾阳虚大鼠行为形态,体重,血细胞,糖、脂、蛋白代谢,心、肝、肾功能,神经、内分泌功能,组织形态学,以及血浆代谢物的异常。这些异常反映了白附片对正常大鼠和肾阳虚大鼠的毒性作用。两者异常的差异表现为所涉及的指标不同,并且同一指标的异常程度有差异,具体可见白附片导致肾阳虚大鼠的异常指标相对较少,异常程度较轻。而且,从某些指标来看,白附片对肾阳虚大鼠有明显的治疗作用。本研究为基于中医证候动物模型评价中药毒性的合理性提供了客观依据,是丰富和完善现代药物毒性评价理论和方法体系的有益探索。
Objective
To observe the difference of Toxic Reaction of white prepared lateral root to normal and kidney yang deficiency rats and explore the rationality of evaluating the toxicity of traditional Chinese herbs based upon traditional Chinese medicine(TCM) syndrome animal model.
Methods
Eighty Sprague-Dawley(SD) male rats were divided randomly into normal and kidney yang deficient model group,forty rats respectively.After producing kidney yang deficient model to rats in model group by injecting hydrocortisoni natrii succinas in intramuscular, normal and model rats were respectively and randomly divided into low,little,medium,great dose group and blank group,eight rats in each group.Those rats were administered orally with different concentrations of white prepared lateral root of aconite every day for two weeks. Taking blood and preparing serum and plasma after anaesthetizating rats.Taking the internal organs(heart,liver,kidney,adrenal gland and spleen),weighing wet heavy and calculating organs coefficient.Fixing the organ with 4%formaldehyde solution,as well as preparing the cardiac muscle organ admixture liquid.
1.The Convention Experiment Study
1.1 Observed Target
Observing the change of rats action,weight and morphology.
TracingⅡcouplet electrocardiogram with Biopac multiple tracks physiology apparatus and recording heart rate(BPM) and peak-to-peak(P-P) as well as arrhythmia.
Blood test:White blood cell total(WBC),red blood cell total(RBC),hemoglobin (HGB) and platelet total(PLT).
Serum biochemistry test:Cholesterol(CHO),total glycerine esters(TG),total protein (TP),glucose(GLU),total bilirubin(T-BIL),urea nitrogen(BUN),urine creatinine(CRE), gamma glutamyl transferase(GGT),uric acid(UAC),glutamic oxaloacetic transaminase (AST),alanine aminotransferase(ALT),creatine Kinase(CK) and lactate dehydrogenase(LDH).
Radioactivity immunity test:Adrenocorticotrophic hormone(ACTH),hydrocortisone (COR),cyclic adenosine monophosphate(cAMP),cyclic guanosine monophosphate(cGMP).
Immunoturbidimetry test:Cardiac muscle Succinate dehydrogenase(SDH) and Na~+-k~+-ATPase enzyme(Na~+-k~+-ATPase).
Dyeing with HE and observing the pathological change of heart,liver,kidney,adrenal gland and spleen with optical microscope.
1.2 Statistical analysis
Quantitative data:adopting one factor analysis of variance,general linear model two factors analysis of variance,covariance analysis,repeated measurement analysis,as well as the straight line regression analysis.Count data:Logistic's regression analysis.P<0.05 was taken to the significance standard.
2.Metabolomics study
Capturing metabolite fingerprint data with the liquid phase color spectrum-mass spectra (LC/MS) metabolomics technology and excavating data orthogonal partial least squares (OPLS).
Results
1.The Convention Experiment Results
1.1 Rats Action,Weight and Morphology Change
As concentration increased,the Toxic Reaction due to action and morphology change of normal rats was more and more evident than model rats'.With low dose of administration, kidney yang deficient syndrome was clearly relieved.The weight of normal and model rats increased with extending time of medication.More dosage accompanied with slighter increase of weight.White prepared lateral root of aconite shown reating effect at low dosage.
1.2 Major Blood Convention Target
Hydrogenation cortisone caused WBC and PLT reduction.After taking white prepared lateral root of aconite,normal rats'WBC and PLT reduced with adding dose,which showed the toxicity effect of white prepared lateral root of aconite.However,model rats'WBC and PLT increased with adding dose,which showed the treating effect of white prepared lateral root of aconite.Hydrogenation cortisone leaded RBC and HGB to reduce,especially HGB reduce much more clearly.White prepared lateral root of aconite had definite influence on normal rats.Mostly representation was that RBC and HGB had the trend of light reduction with adding dose.As to model rats,low dose white prepared lateral root of aconite could raise blood RBC and HGB level.
1.3 Serum Glucose,Ester and Protein Level
Hydrogenation cortisone caused GLU reduce.After taking white prepared lateral root of aconite,normal rats' GLU reduced with adding dose,which showed the toxicity effect of white prepared lateral root of aconite.However,model rats' GLU increased with adding dose, which showed the treating effect of white prepared lateral root of aconite.Hydrogenation cortisone leaded TG to go up.Taking medicine made model rats' TG have a trend of reduction with adding dose.Moreover,taking white prepared lateral root of aconite could make normal rats' CHO and TP go up.
1.4 Heart Function
White prepared lateral root of aconite could cause normal rats and model rats arrhythmia. With the increase of dosage,the occurring rate of arrhythmia went up.The occurring rate of arrhythmia of model rats is lower than normal rats',which pointed out that white prepared lateral root of aconite had more great infaust influence on normal rats.White prepared lateral root of aconite could quicken heart rate and P-P vaule of rats,and both were inclined to quicken with adding dose.The increasing extent of heart rate of model rats was lower than normal rats',but it's the increasing extent of P-P vaule was consistent to normal rats'.
With adding dose,all rats heart coefficient and LDH squinted towards going up.Normal rats'LDH going up was quicker than model rats',which indicated abnormal influence on surrounding cardiac muscle enzyme.With adding dose,all rats SDH and Na~+-K~+-ATPase had a trend of descending.Normal rats' SDH descending was quicker than model rats',which showed white prepared lateral root of aconite also impacted rats'cardiac muscle mitochondrion enzyme.
1.5 Liver and Kidney Function
With adding dose,all rats ALT squinted towards going up,but ALT of normal rats went up more quickly than model rats,which suggested white prepared lateral root of aconite caused more liver toxicity to normal rats.In addition,white prepared lateral root of aconite also produced kidney toxicity to normal rats.
1.6 Nerve and Endocrine Function
Hydrogenation cortisone caused cAMP and COR descend,cGMP increase.With adding dose,cAMP/cGMP and COR of normal rats inceased,both adrenal gland coefficient auxed, but chest gland coefficient descend.
1.7 Morphology Change of Pathology Organ
White prepared lateral root of aconite caused both rats organ morphology change in heart, liver,kidney,adrenal gland and spleen.Trauma extent became serious gradually with adding dose.To same internal organ and same dose medicine,the pathology change of model rats was slighter than normal rats.
2.Metabolomics Study Result
Metabolomics study indicated that Lysophosphatidyl choline(LPC) and lysophosphatidyl ethanolamine(LPE) were chief material symbols among various metabolite in normal and model rats caused by white prepared lateral root of aconite.LPC and LPE had different change trend between normal and model rats with dose change.
Conclusion
This study showed that white prepared lateral root of aconite could cause abnormity in normal rats and kidney yang deficiency rats as following:action and morphology,weight, major blood convention target,serum glucose,serum lipid and protein level,heart function, liver and kidney function,nerve and endocrine function,pathology organ change,and plasma metabolite change.All abnormal changes reflected toxicity effect of white prepared lateral root of aconite to normal and kidney yang deficiency rats.The abnormal targets in kidney yang deficiency model rats were less than in normal rats both in quantity and degree. Moreover,white prepared lateral root of aconite shown treating effect to model rats by some abnormal targets.This study provided objective evidence for the theory of evaluating traditional Chinese herbs toxicity based on TCM syndrome animal model,which proved to be a beneficail exploration in enriching modern medicine toxicity evaluation system.
引文
[1]廖明阳,吴纯启.药物毒理学研究的发展现状与趋势.毒理学杂志,2007,21(5):356-358.
[2]王全军,吴纯启,廖明阳.药物毒理学研究新进展.中国新药杂志,2007,16(3):177.181.
[3]周建良,齐炼文,李萍.色谱指纹图谱在中药质量控制中的应用.色谱,2008,26(2):153-159.
[4]Xie Y,Jiang ZH,Zhou H,et al.Combinative method using HPLC quantitative and qualitative analyses for quality consistency assessment of a herbal medicinal preparation.Pharm Biomed Anal,2007,43(1):204-212.
[5]冯俭,谢萍.中药有效成分理化性质分析在新药开发研究中的重要意义与基本方法.中国中药杂志,2003,28(9):798-800.
[6]Pennie WD,Tugwood JD,Oliver GJ,et al.The principles and practice of toxicogenomics:applications and opportunities.Toxicol Sci,2000,54(2):277-283.
[7]Singh SS.Preclinical Pharmacokinetics:an approach towards safer and efficacious drugs.Curr drug Metab,2006,7:165-182.
[8]Yuan H,Wang YY,Cheng YY.Local and global quantitative structure-activity relationship modeling and Prediction for the baseline toxicity.Chem Inf Model,2007,47:159-169.
[9]Hughes TR,Marton MJ,Jones AR,et al.Functional discovery via a compendium of expression profiles.Cell,2000,102(1):109-126.
[10]吕爱平.中药现代化发展新要求——应重视中药适应症和中药药效评价的研究.首都医药,2003,(2):27-30.
[11]简晖,谭勇,赵静,等.基于中医证候分类理论的中药安全性评价研究思路和方法.中国中医基础医学杂志,2008,14(9):652-654.
[12]袁伯俊,佘佳红,陆国才.创新药物非临床安全性研究应注意的若干问题.毒理学杂志,2007,21(4):277-278.
[13]任进.毒性病理学基本原则和方法的探讨.毒理学杂志,2007,2l(4):280-281.
[14]程树军,黄韧.GLP药物安全性评价中毒性病理学存在的问题及对策.中国比较医学杂志,2007,17(1):51.54.
[15]林海霞,常艳,马璟.药物的免疫毒性评价.世界临床药物,2008,29(7):430-433.
[16]袁守军.当前新药毒代动力学的研究概况与不足.毒理学杂志,2007,21(4): 297-298.
[17]Inoue T.Toxicogenomics,a new paradigm of toxicology.Tokyo:Springer Ver Lag,2003:3-11.
[18]Bartosiewicz M,Trounstine M,Barker D,et al.Development of a toxicological gene array and quantitative assessment of this technology.Arch Biochem Biophys,2000,376(1):66-73.
[19]李攻戌.中药新药临床安全性评价.中药新药与临床药理,2005,16(1):3-5.
[20]吕爱平,陈明人,简晖,等.中药现代化研究应重视与中医现代化研究的结合.中国中医药信息杂志,2003,10(8):3-4.
[21]吕爱平.多次反复临床试验找到精确适应症是提高中医药疗效的重要途径.中国中西医结合杂志,2006,26(7):588-589.
[22]叶祖光.中药毒理学的研究思路.世界科学技术——中医药现代化,2003,5(6):1-5.
[1]Wang J Z,Han G Y.Studies on alkaloids isolated from Aconitum crmichaeli Debx.Acta PharmSin,1985,20(1):71-73.
[2]Zhang W D,Han G Y,Liang H G,et al.Studies on the alkaloid constituents of JIANGYOU FU-ZI(Aconitum-carmichaeli) from Sichuan.Acta PharmSin,1992,27(9):670-673.
[3]Ko RJ.Perspective on the adverse reactions from traditional Chinese medicines.J Chin MerlAssoc,2004,67(3):109.
[4]Lord G M,Tagore R,Cook T,et al.Nephropathy caused by Chinese herbs in the UK. Lancet.1999,354(9177):481-482.
[5]Mizugaki M,Ito K,Ohyama Y,et al.Quantitative analysis of Aconitum alkaloids in the urine and serum of male attempting suicide by oral intake of aconitine extract.J Anal Toxicol,1998,22(4):336-340.
[6]Bello-Ramirez AM,Nava-Ocampo AA.A QSAR analysis of toxicity of Aconitum alkaloids.Fundam Clin Pharmacol,2004,18(6):699-704.
[7]雷载权.中华临床中药学.北京:人民卫生出版社,1984:727.
[8]王浴生.中药药理与应用.北京:北京科技出版社,2000:592.
[9]黄泰康.常用中药成分与药理手册.北京:中国医药科技出版社,1994:921-927.
[10]孙小侠.有毒中药药性药理及临床研究应用实用手册.北京:当代中国音像出版社,2004:796.
[11]王洪章.浅谈附子之毒.天津中医药,2003;20(6):64.
[12]杨小欣.浅谈附子的毒性反应及防范措施.辽宁中医学院学报,2003,5(2):162.
[13]李宗浩.现代急救医学.杭州:浙江科学出版社,1993:408.
[14]李云霞,顾风云.急性乌头碱中毒2例.中国中西医结合急救杂志,1995,2(1):30.
[15]周远鹏.附子及其主要成分的药理作用及毒性.药学学报,1983,18(5):394.
[16]杨晓敏.实用急性中毒手册.成都:四川科学技术出版社,1991:252.
[17]Zhou SS,Yang J,LI YQ,et al.Effect of Cl~--channel blockers on aconitine-induced arrhythmias in rat heart.Exp Physiol.2005,90(6):865-872.
[18]Sawanobori T,Adaniya H,Hirano Y,et al.Effects of anti-arrhythmias agents and Mg2+on aconitine-induced arrhythmias.Jpn Heart.1996,37(5):709-718.
[19]余化平,陈生福,王刚平.乌头碱中毒致心律失常16例临床分析.医学研究通讯,1993,22(8):31.
[20]邓士贤.云南医学杂志.1963,2:40-44.
[21]Hatta E,Yasuda K,Levi R.Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia. J Pharmacol Exp Ther,1997,283(2):494-500.
[22]Friese J,Gleitz J,Gutser UT.Aconitum alkaloids:the modulation of voltage-dependent Na+ channels,toxicity and antinociceptive proerties.Eur J of Pharmaco,1997,337(2-3):165-174.
[23]Nilius B,Benndorf K,Markwardt F.Modified gating behavior of aconitine treated single sodium channels from adult cardiacmyocytes.P flugers Arch,1986,407(6):691-693.
[24]Sauviat MP.Effect of neurotoxins on the electrical activity and contraction of the heart muscle.C R Seances Soc Biol Fil,1997,191(3):451-471.
[25]Puletti M,Mariani M,Jacobellis GF,et al.Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins.Cell Signal,2003,15(2):151-159.
[26]杨宝峰,单宏丽,龚冬梅,等.抗心律失常药物作用最佳靶点研究.哈尔滨商业大学学报.2002,8(1):1-5.
[27]Wright SN.Comperison of aconitine-modified human heart(hHl) and rat skeletal(mul)muscle Na+ channels:an important role for external Na+ ions.J Physiol,2002,538(Pt3):759-771.
[28]Duan JH,Xing JL,Yang J,et al.Different firing patterns induced by verntridine and aconitine in injured dorsal root ganglion neurous.Acta Physiol Sin,2005,57(2):169-174.
[29]Ohno Y,Chiba S,Uchigasaki S,et al.The influence of tetrodotoxin on the toxic effects of aconitine in vivo.Tohoku J Exp Med,1992,167(2):155-158.
[30]陈龙,马聘,蔡宝昌,等.乌头碱对大鼠心肌细胞钙通道阻滞作用的单通道分析.药学学报.1995,30(3):168-169.
[31]Yang KS.Effect of the aconitum tuber butanaol fracion on the contractile protein of myocardium.Taehan Yakrihak Chapchi,1976,12(1):23.
[32]梁强荣,刘明俊,胡炳蔚.大鼠乌头碱中毒心肌酶的细胞化学研究(4).中国法医学杂志,1991,6(3):140.
[33]Shimizu Hiroshi.NUR study of aconitine poisoning.Wakan Iyaku Cakkaishi,1985,2(3):23.
[34]李宏,陈念祖,刘明俊,等.大鼠乌头碱中毒心肌酶的细胞化学研究(1).中国法医学杂志.1988,3(4):199-202.
[35]梁强荣,刘明俊,胡炳蔚.大鼠乌头碱中毒心肌酶的细胞化学研究(3).中国法医学杂志,1991,6(2):84.
[36]潘燕,张述禹,候金凤.诃子对乌头碱致心肌细胞损伤的影响.中国民族医药杂志,2002,8(1):32-33.
[37]雷怀成,宋道江,易建华,等.大鼠乌头碱中毒心肌细胞凋亡的研究.中国工业医学杂志,2004,17(6):373-374.
[1]冯海莲,黄秀梅,王宁萍.考察复方锁阳胶囊的温肾助阳作用.中成药,2005,27(1):105.
[2]皋聪,王传社,巫冠中,等.苁蓉总苷对氢化可的松致肾阳虚小鼠学习记忆功能的影响.中国中医基础医学杂志,2005,11(5):330-332.
[3]郭瑞新,蔡承妹.冬虫夏草提高“肾阳虚”小鼠生殖功能的实验研究.基层中药杂志,2002,16(2):325.
[4]Besedovsky Ho,Sorkin E,Felix D.Hypothalamic changes during the immune response.Eur J Immunol,1977(5):323-325.
[5]Basedovsky Ho,Sorkin E.Network of immuno-neuroendocrine interations.Chin Exp Immunol,1977,27(1):1.
[6]沈自尹.肾阳虚证的定位研究.中国中西结合杂志,1997,17(1):50-51.
[7]沈自尹.从肾本质研究到证本质的思考与实践.上海中医药杂志,2000,(4):6.
[8]陈英华,欧阳轶强,孙琪,等.肾阳虚证动物模型规范化研究中诊断指标选择的初步探讨.中国中医基础医学杂志,2003,9(10):26-30.
[9]郑里翔,刘晓庄,王莉,等.肾阳虚对大脑神经递质、胆碱酯酶的影响.新中医,2000,32(5):31-32.
[10]宋春风,尹桂山,李恩,等.补肾中药对肾阳虚大鼠下丘脑-垂体-肾上腺轴Fos蛋白表达的影响.中国中医基础医学杂志,2001,7(10):38-40.
[11]宋春风,郑师陵,吕佩源,等.补肾中药对肾阳虚大鼠下丘脑-垂体-肾上腺轴、血淋巴细胞Ca~(2+)和血清钙的影响.中国中医基础医学杂志,2002,8(5):34-36.
[12]宋春风,尹桂山,赵建宏.补肾中药对肾阳虚大鼠下丘脑-垂体-肾上腺轴cAMPKⅡ 的影响.中国中医基础医学杂志,2001,7(8):45-47.
[13]蒋淑君,王桂兰,许兰芝.糖皮质激素对HPAA的影响及仙灵脾的调整作用.滨州医学院学报,2004,27(2):88-90.
[14]宋春风,尹桂山,孙素,等.右归饮对肾阳虚大鼠下丘脑.垂体.肾上腺轴钙调素mRNA表达的影响.中国中医基础医学杂志,2001,7(3):20-22.
[15]钟历勇,沈自尹,蔡定芳,等.补肾健脾活血三类复方对下丘脑.垂体-肾上腺-胸腺轴及CRF基因表达的影响.中国中西医结合杂志,1997,17(1):39-41.
[16]高博,姚玉霞,张效云,等.肾阳虚大鼠下丘脑神经元型NOSmRNA表达及补肾药的调整作用.中国中医基础医学杂志,2001,7(8):23-24.
[17]高博,尹桂山.补肾药对肾阳虚大鼠下丘脑组织蛋白激酶活性的影响.中国中医基础医学杂志,2000,6(1):30-33.
[18]秦路平,张家庆.蛇床子香豆素对肾阳虚模型大鼠腺垂体-肾上腺皮质轴功能的影响.中国中西医结合杂志,1997,17(4):227-229.
[19]刘旭光,宋开源,余曙光,等.阴虚阳虚大鼠促肾上腺皮质激素及皮质酮昼夜节律的差异研究.四川中医,2002,20(1):6.
[20]宋春风,尹桂山,李恩,等.右归饮对肾阳虚大鼠下丘脑正中隆起室管膜细胞的影响.中国中医基础医学杂志,2001,7(1):19-22.
[21]宋春风,尹桂山,侯洁,等.补肾中药对肾阳虚大鼠垂体-肾上腺超微结构的影响.中医药研究,2001,17(2):41-42.
[22]李春生,张国玺,石体仁,等.山茱萸水溶性总提取物对肾阳虚动物模型生命质量和肾上腺组织的影响.中医杂志,2001,42(8):491.
[23]郭凯,徐蓉,俞伟,等.金匮肾气丸对肾阳虚动物模型影响的拆方研究.中医药学报,2003,31(1):20-21.
[24]宋春风,尹桂山,李恩,等.补肾益气中药对肾阳虚大鼠垂体.甲状腺超微结构的影响.中国中医基础医学杂志,1999,5(9):22-24.
[25]蒋淑君,崔存德,许兰芝.阳虚大鼠下丘脑.垂体.性腺轴钙调蛋白基因表达及补肾中药的调整作用.中国临床康复,2004,8(24):5056-5057.
[26]薛莎,汤学军.右归丸对肾阳虚动物模型血液微量元素含量的影响.中国中医药科技,2002,7(3):168-169.
[27]李春生,张国玺,石体仁,等.山茱萸水提取物对肾阳虚动物模型肝脏和睾丸影响的实验研究.中国中药杂志,2003,28(8):743-746.
[28]宋春风,马洪骏,吕佩源,等.补肾中药对肾阳虚大鼠垂体-睾丸超微结构的影响.中医药研究,2001,17(4):45-46.
[29]刘永琦,王文,虚证的免疫学本质.中国中医基础医学杂志,2003,9(5):7-10.
[30]冼国新,陈林香,戴馨仪,等.健脾补肾对正常小鼠和小鼠虚证模型一些免疫功能的实验研究.广州中医学院学报,1984,1(2):17-21.
[31]张建民,沈翔.“肾阳虚”小鼠免疫功能变化.浙江中医杂志,2002,19:260.
[32]马健,樊巧玲.阳虚模型小鼠腹腔巨噬细胞Ia抗原表达及乌头碱的作用.中国中西医结合杂志,1995,15(9):544-546.
[33]高梅.大黑蚂蚁水提液对阳虚动物模型免疫功能的影响.中国老年医学杂志,1999,19(1):49-50.
[34]李瑞荃,王明芳,潘学会,等.“益视明”对实验性肾阳虚大鼠红细胞免疫功能的影响.成都中医药大学学报,1997,20(1):41-42.
[35]施玉华.研究助阳药和滋阴药对阳虚动物模型的作用.上海中医药杂志,1981,(12):39.
[36]杜标炎,李道中,王培训.肾阳虚造型及补肾中药对大鼠免疫功能的影响.广州中医药大学学报,1996,13(1):37-39.
[37]雷娓娓,黄真炎,郑高飞,等.肾虚、脾虚造型动物免疫超微结构的比较研究.深圳中西医结合杂志,1999,9(2):14-15.
[38]王钰霞,陈魁敏.真武汤对阳虚小鼠作用的实验研究.中国实验方剂学杂志,2002,7(1):48-49.
[39]任丽民,刘承备.温脾汤治疗“肾阳虚”大鼠的实验研究.北京实验动物科学与管理,1994,11(3):34-36.
[40]黄厚才,彭蕴茹,沈明勤.金匮肾气丸对大鼠肾阳虚模型的影响.中国比较医学杂志,2004,14(3):155-157.
[41]王普京,严智强.氢化可的松动物模型的病理组织学观察及其中药的反证与治疗.中国中医基础医学杂志,1999,5(10):41-42.
[42]邝安堃,丁霆,陈家伦,等.阳虚(甲状腺功能减退)和阴虚(甲状腺功能亢进)病人血浆环核苷酸的对比.中医杂志,1979,7(7):21-24.
[43]何明大,杨锡兰,杨剑纲,等.保元口服液对阳虚小鼠血SOD、LPO及VitE的影响.湖南医科大学学报,1994,19(5):459-460.
[44]郑军,骆永珍.川产淫羊藿对“阳虚”模型动物血浆中分子物质与巯基含量的影响. 中国中药杂志,1995,2(4):238-239.
[45]薛莎,汤学军.微量元素测定对右归丸治疗家兔肾阳虚疗效的评价.湖北中医学院学报,2003,2(1):18-20.
[46]马威,薛莎,吴文莉.肾阳虚模型血液微量元素的聚类分析.数理医药学杂志,2000,13(2):127-128.
[47]秦路平,石汉平,王洪斌,等.蛇床子香豆素对肾阳虚模型大鼠学习记忆和神经肽的影响.第二军医大学学报,1997,18(2):147-149.
[48]司卉良,陈友香,侯安继,等.补肾汤对激素致更年期肾阳虚证大鼠卵巢功能的影响.中药药理与临床,2005,21(2):44-45.
[49]张婷,何嘉琳.育麟方对肾阳虚大鼠排卵功能的影响.现代中西医结合杂志,2005,14(16):2111-2113.
[50]刘蓬,卢标清,邱宝珊,等.不同补肾法对肾阳虚豚鼠模型听力的影响.现代康复,2001,5(11):58-59.
[51]邹世洁,陈小野.小鼠甲状腺机能减退肾阳虚模型的胃粘膜病理研究.吉林中医药,1997,(6):86-87.
[1]Nicholson JK,Wilson ID.Understanding global systems biology:Metabonomics and the continuum of metabolism.Nat Rev Drug Discov,2003,2(8):668-676.
[2]Brindle JT,Antti H,Holmes E,et al.Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H NMR-based metabonomics.NatMed,2002,8(12):1439-1444.
[3]Griffin JL,Bonney SA,Mann C,et al.An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver.PhysiolGenomics,2004,17(2):140-149.
[4]Henry CM.The"metabonome" provides real-world information about drug toxicity,gene function.Chem Eng News,2002,80(48):66.
[5]Hector C.Metabonomic modeling of drug toxicity.Pharmacology &Therapeutics,2006,109(1-2):92-106.
[6]Garrod S,Humpfer E,Sprau LM,et al.High-resolution magic angle spinning 1H NMR spectroscopic studies on intact rat renal cortex and medulla.Magn Reson Med,1999,41(6):1108-1118.
[7]Garrod S,Humpher E,Connor SC,et al.High resolution 1H-NMR and magic angle spinning NMR spectroscopic investigation of the biochemical effects of 2-bromoethanamine in intact renal and hepatic tissue.Magn ResonMed,2001,45(5):781-790.
[8]Williams RE,Major H,Lock EA,et al.D-Serine-in-duced nephrotoxicity:a HPLC-TOF/MS-based metabonomics approach.Toxicology,2005,207(2):179-190.
[9]Wilson ID,Nicholson JK,Castro-Perez,et al.High resolution "Ultra performance" liquid chromatography coupled to TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies.J Proteome Res,2005,4(2):591-598.
[10]Lord G M,Tagore R,Cook T,et al.Nephropathy caused by Chinese herbs in the UK.Lancet,1999,354(9177):481-482.
[11]李晶,吴晓健,刘昌孝,等.代谢组学研究中数据处理新方法的应用.药学学报,2006,41(1):47-53.
[12]Ebbels T,Keun H,Beckonert O,et al.Toxicity classification from metabonomic data using a density superposition approach:"CLOUDS".Anal Chim Acta,2003,490(1-2):109-122.
[13]Shockcor JP,Holmes E.Metabonomics applications in toxicity screening and disease diagnosis.Curr Top Med Chem,2002,2(1):35.
[14]Wright SN.Comperison of aconitine-modified human heart(hH1) and rat skeletal(mu1)muscle Na+ channels:an important role for external Na+ ions.J Physiol.2002,538(Pt 3):759-771.
[15]Slim RM,Roberstson DG,Ajbassam M,et al.Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats.Toxicol Appl Res,2003,183(2):108.
[16]彭双清,廖艳,领贤忠.药物毒性作用机制的代谢组学.毒理学杂志,2005,19(3)增刊:175.
[17]Soga T,Baran R,Suematsu M,et al.Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption.J Biol Chem,2006,281(24):16768-16776.
[18]Yang J,Zhao X,Liu X,et al.High performance liquid chromatography-mass spectrometry for metabonomics:potential biomarkers for acute deterioration of liver function in chronic hepatitis B.Proteome Res,2006,5(3):554.
[19]刘昌孝.代谢组学的发展与药物研究开发.天津药学,2005,17(2):1-6.
[20]Ko RJ.Perspective on the adverse reactions from traditional Chinese medicines.J Chin Merl Assoc,2004,67(3):109.
[21]Liu CX.Metabonomics in modern research of traditional Chinese medicines.Chinese Traditional and Herb Drugs,2004,35(6):601.
[22]赵剑宇,颜贤忠,彭双清.关木通肾毒性的代谢组学研究.中草药,2006,37(5):725-730.
[23]Goodacre R,Vaidyanathan S,Dunn WB,et al.Metabolomics by numbers:acquiring and understanding global metabolite data.Trends Biotechnol,2004,22(5):245.
[24]Nielsen J,Oliver S.The next wave in metabolome analysis.Trends Biotechnol,2005,23(11):544.
[25]Thomas CE,Ganji G.Integration of genomic and metabonomic data in systems biology are we "there" yet?Curr Opin Drug Discov Devel,2006,9(1):92.
[26]Coen M,Lenz EM,Nicholson JK,et al.An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy.Chem Res Toxicol,2003,16(3):295-303.
[1]薛文礼.从中药的安全性谈中药的国际化.中医药信息,2005,2(22):6-7.
[2]周宜.从《内经》“有故无殒”思想看中药毒性研究.中国中医基础医学杂志.2007,13(5):342-343.
[3]王丽霞,陆丽珠.中药安全性探讨.药物不良反应杂志,1999,1(2):88-91.
[4]刘树民,李玉洁,罗明媚.中药毒性研究及思路探讨.世界科学技术—中医药现代化.2003,5(2):21-23.
[5]张立东.中药的有毒与无毒探析.中医药学刊,2006,24(10):1946-1947.
[6]陈学习,彭成.对附子毒性的再认识.辽宁中医药大学学报,2007,9(6):7-8.
[7]朱林平.附子毒性研究概况.江西中医药,2004,35(6):53-55.
[8]凌一揆.中药学.上海科学技术出版社,1985,108.
[9]邝安堃,吴裕,丁霆,等.某些助阳药对于大剂量皮质素所致耗竭现象的影响.中华内科杂志,1963,2:113-116.
[10]李勇枝.中医肾虚证研究进展.中国中医基础医学杂志,1996,2(4):56-60.
[11]钟历勇,沈自尹,蔡定芳,等.补肾健脾活血三类复方对下丘脑-垂体-肾上腺-胸腺轴及CRF基因表达的影响.中国中西医结合杂志,1997,17(1):39-41.
[12]陈奇.阴虚、阳虚动物模型和中药作用与评价.中药药理与临床,1991,7(5):47-48.
[13]张新民,段元丽,沈自尹,等.三类中药复方对侧脑室内注射IL-1大鼠下丘脑-垂体-肾上腺皮质轴反应状态的影响.中医杂志,2002,43(1):59-62.
[14]Chrousos GP.The hypothalamic-Pituitary-adrenal axis and immune-mediated inflammation.N Engl JMed,1995,332:1351-1362.
[15]Cho YM,Kim SY,Cho BY,et al.Dissociation between Plasma adrenoCORticotropin and serum CORtisol level during the early postoperative period after gastrectomy.Horm Res,2000,53:246-250.
[16]Nicholson JK,Connelly J,Lindon JC.,et al.Metabonomics:a platform for studying drug toxicity and gene function.Nat Rev Drug Diacov,2002,1(2):153-161.
[17]Zhang X,Wu H,Liao P,et al.NMR-based metabonomic study on the eubacute toxicity of ariatolochic acid in rats.Food Chemical Toxicology,2006,44:1006-1014.
[18]Coen M,Lenz EM,Nicholson JK,et al.An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR aspectroscopy.Chemical Research Toxicology,2003,16(3):295-303.
[19]Lindon JC.,Nicholson JK,HolmesE,et al.Contemporary issues in toxicology,the role of metabonomics in toxicology and its evaluation by the COMET project.Toxicol Appl Pharmacol,2003,187:1371.
[20]Ogiso H,Suzuki T,Taguchi R.Development of a reverse-phase liquid chromatography electrospray ionization mass spectrometry method for lipidomics,improving detection of phosphatidic acid and phosphatidylserine.Anal Biochem,2008,375(1):124-131.
[21]Yu K,Sheng G,Sheng J,et al.A metabonomic investigation on the biochemical Perturbation in liver failure Patients caused by hepatitis B virus.J Proteome Res,2007,6(7):2413-2419.
[22]Yang J,Zhao X,Liu X,et al.High Performance liquid chromatography-mass spectrometry for metabonomics:potential biomarkers for acute deterioration of liver function in chronic hepatitis.J Proteome Res,2006,5(3):554-561.
[23]Kaden J J,Dempfe CE,Sueselbeek T,et al.Time dependent in the plasma concentration of matrix met alloproteinase after acute myocardial infarction.Cardiology,2003,99(3):140-144.
[24]Chien CH,Yen MH,Liu HW,et al.Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cell:in comparison with oxidized LDL.Atherosclerosis,2000,151:481-491.
[25]Hiroharu K,Noriaki K,SusumuM,et al.Oxidized LDL modulates Bax/Bcl-2 through the lectinlike ox-LDL receptor-1 in vascular smooth muscle cell.Arterioscler Thromb Vase Biol,2001,21:955-960.
[26]Ren S,Shatadal S,Shen GX.Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells.Am J Physiol Endocrinol Metab,2000,278(4):656-662.
[27]周爱儒.生物化学.北京:人民卫生出版社,2000,123-130.
[25]Poutanen SM,Low DE,Henry B,et al.Identification of severe acute respiratory syndrome in Canada.N Engl J Med,2003,348(20):1995-2005.
[29]李春生,张国玺,石体仁,等.山茱萸水提取物对肾阳虚动物模型肝脏和睾丸影响的实验研究.中国中药杂志,2003,28(8):743-746.
[30]Shimizu Hiroshi.NUR study of aconitine poisoning.Wakan Iyaku Cakkaishi,1985,2(3):23.
[2]王全军,吴纯启,廖明阳.药物毒理学研究新进展.中国新药杂志,2007,16(3):177.181.
[3]周建良,齐炼文,李萍.色谱指纹图谱在中药质量控制中的应用.色谱,2008,26(2):153-159.
[4]Xie Y,Jiang ZH,Zhou H,et al.Combinative method using HPLC quantitative and qualitative analyses for quality consistency assessment of a herbal medicinal preparation.Pharm Biomed Anal,2007,43(1):204-212.
[5]冯俭,谢萍.中药有效成分理化性质分析在新药开发研究中的重要意义与基本方法.中国中药杂志,2003,28(9):798-800.
[6]Pennie WD,Tugwood JD,Oliver GJ,et al.The principles and practice of toxicogenomics:applications and opportunities.Toxicol Sci,2000,54(2):277-283.
[7]Singh SS.Preclinical Pharmacokinetics:an approach towards safer and efficacious drugs.Curr drug Metab,2006,7:165-182.
[8]Yuan H,Wang YY,Cheng YY.Local and global quantitative structure-activity relationship modeling and Prediction for the baseline toxicity.Chem Inf Model,2007,47:159-169.
[9]Hughes TR,Marton MJ,Jones AR,et al.Functional discovery via a compendium of expression profiles.Cell,2000,102(1):109-126.
[10]吕爱平.中药现代化发展新要求——应重视中药适应症和中药药效评价的研究.首都医药,2003,(2):27-30.
[11]简晖,谭勇,赵静,等.基于中医证候分类理论的中药安全性评价研究思路和方法.中国中医基础医学杂志,2008,14(9):652-654.
[12]袁伯俊,佘佳红,陆国才.创新药物非临床安全性研究应注意的若干问题.毒理学杂志,2007,21(4):277-278.
[13]任进.毒性病理学基本原则和方法的探讨.毒理学杂志,2007,2l(4):280-281.
[14]程树军,黄韧.GLP药物安全性评价中毒性病理学存在的问题及对策.中国比较医学杂志,2007,17(1):51.54.
[15]林海霞,常艳,马璟.药物的免疫毒性评价.世界临床药物,2008,29(7):430-433.
[16]袁守军.当前新药毒代动力学的研究概况与不足.毒理学杂志,2007,21(4): 297-298.
[17]Inoue T.Toxicogenomics,a new paradigm of toxicology.Tokyo:Springer Ver Lag,2003:3-11.
[18]Bartosiewicz M,Trounstine M,Barker D,et al.Development of a toxicological gene array and quantitative assessment of this technology.Arch Biochem Biophys,2000,376(1):66-73.
[19]李攻戌.中药新药临床安全性评价.中药新药与临床药理,2005,16(1):3-5.
[20]吕爱平,陈明人,简晖,等.中药现代化研究应重视与中医现代化研究的结合.中国中医药信息杂志,2003,10(8):3-4.
[21]吕爱平.多次反复临床试验找到精确适应症是提高中医药疗效的重要途径.中国中西医结合杂志,2006,26(7):588-589.
[22]叶祖光.中药毒理学的研究思路.世界科学技术——中医药现代化,2003,5(6):1-5.
[1]Wang J Z,Han G Y.Studies on alkaloids isolated from Aconitum crmichaeli Debx.Acta PharmSin,1985,20(1):71-73.
[2]Zhang W D,Han G Y,Liang H G,et al.Studies on the alkaloid constituents of JIANGYOU FU-ZI(Aconitum-carmichaeli) from Sichuan.Acta PharmSin,1992,27(9):670-673.
[3]Ko RJ.Perspective on the adverse reactions from traditional Chinese medicines.J Chin MerlAssoc,2004,67(3):109.
[4]Lord G M,Tagore R,Cook T,et al.Nephropathy caused by Chinese herbs in the UK. Lancet.1999,354(9177):481-482.
[5]Mizugaki M,Ito K,Ohyama Y,et al.Quantitative analysis of Aconitum alkaloids in the urine and serum of male attempting suicide by oral intake of aconitine extract.J Anal Toxicol,1998,22(4):336-340.
[6]Bello-Ramirez AM,Nava-Ocampo AA.A QSAR analysis of toxicity of Aconitum alkaloids.Fundam Clin Pharmacol,2004,18(6):699-704.
[7]雷载权.中华临床中药学.北京:人民卫生出版社,1984:727.
[8]王浴生.中药药理与应用.北京:北京科技出版社,2000:592.
[9]黄泰康.常用中药成分与药理手册.北京:中国医药科技出版社,1994:921-927.
[10]孙小侠.有毒中药药性药理及临床研究应用实用手册.北京:当代中国音像出版社,2004:796.
[11]王洪章.浅谈附子之毒.天津中医药,2003;20(6):64.
[12]杨小欣.浅谈附子的毒性反应及防范措施.辽宁中医学院学报,2003,5(2):162.
[13]李宗浩.现代急救医学.杭州:浙江科学出版社,1993:408.
[14]李云霞,顾风云.急性乌头碱中毒2例.中国中西医结合急救杂志,1995,2(1):30.
[15]周远鹏.附子及其主要成分的药理作用及毒性.药学学报,1983,18(5):394.
[16]杨晓敏.实用急性中毒手册.成都:四川科学技术出版社,1991:252.
[17]Zhou SS,Yang J,LI YQ,et al.Effect of Cl~--channel blockers on aconitine-induced arrhythmias in rat heart.Exp Physiol.2005,90(6):865-872.
[18]Sawanobori T,Adaniya H,Hirano Y,et al.Effects of anti-arrhythmias agents and Mg2+on aconitine-induced arrhythmias.Jpn Heart.1996,37(5):709-718.
[19]余化平,陈生福,王刚平.乌头碱中毒致心律失常16例临床分析.医学研究通讯,1993,22(8):31.
[20]邓士贤.云南医学杂志.1963,2:40-44.
[21]Hatta E,Yasuda K,Levi R.Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release in a human model of protracted myocardial ischemia. J Pharmacol Exp Ther,1997,283(2):494-500.
[22]Friese J,Gleitz J,Gutser UT.Aconitum alkaloids:the modulation of voltage-dependent Na+ channels,toxicity and antinociceptive proerties.Eur J of Pharmaco,1997,337(2-3):165-174.
[23]Nilius B,Benndorf K,Markwardt F.Modified gating behavior of aconitine treated single sodium channels from adult cardiacmyocytes.P flugers Arch,1986,407(6):691-693.
[24]Sauviat MP.Effect of neurotoxins on the electrical activity and contraction of the heart muscle.C R Seances Soc Biol Fil,1997,191(3):451-471.
[25]Puletti M,Mariani M,Jacobellis GF,et al.Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins.Cell Signal,2003,15(2):151-159.
[26]杨宝峰,单宏丽,龚冬梅,等.抗心律失常药物作用最佳靶点研究.哈尔滨商业大学学报.2002,8(1):1-5.
[27]Wright SN.Comperison of aconitine-modified human heart(hHl) and rat skeletal(mul)muscle Na+ channels:an important role for external Na+ ions.J Physiol,2002,538(Pt3):759-771.
[28]Duan JH,Xing JL,Yang J,et al.Different firing patterns induced by verntridine and aconitine in injured dorsal root ganglion neurous.Acta Physiol Sin,2005,57(2):169-174.
[29]Ohno Y,Chiba S,Uchigasaki S,et al.The influence of tetrodotoxin on the toxic effects of aconitine in vivo.Tohoku J Exp Med,1992,167(2):155-158.
[30]陈龙,马聘,蔡宝昌,等.乌头碱对大鼠心肌细胞钙通道阻滞作用的单通道分析.药学学报.1995,30(3):168-169.
[31]Yang KS.Effect of the aconitum tuber butanaol fracion on the contractile protein of myocardium.Taehan Yakrihak Chapchi,1976,12(1):23.
[32]梁强荣,刘明俊,胡炳蔚.大鼠乌头碱中毒心肌酶的细胞化学研究(4).中国法医学杂志,1991,6(3):140.
[33]Shimizu Hiroshi.NUR study of aconitine poisoning.Wakan Iyaku Cakkaishi,1985,2(3):23.
[34]李宏,陈念祖,刘明俊,等.大鼠乌头碱中毒心肌酶的细胞化学研究(1).中国法医学杂志.1988,3(4):199-202.
[35]梁强荣,刘明俊,胡炳蔚.大鼠乌头碱中毒心肌酶的细胞化学研究(3).中国法医学杂志,1991,6(2):84.
[36]潘燕,张述禹,候金凤.诃子对乌头碱致心肌细胞损伤的影响.中国民族医药杂志,2002,8(1):32-33.
[37]雷怀成,宋道江,易建华,等.大鼠乌头碱中毒心肌细胞凋亡的研究.中国工业医学杂志,2004,17(6):373-374.
[1]冯海莲,黄秀梅,王宁萍.考察复方锁阳胶囊的温肾助阳作用.中成药,2005,27(1):105.
[2]皋聪,王传社,巫冠中,等.苁蓉总苷对氢化可的松致肾阳虚小鼠学习记忆功能的影响.中国中医基础医学杂志,2005,11(5):330-332.
[3]郭瑞新,蔡承妹.冬虫夏草提高“肾阳虚”小鼠生殖功能的实验研究.基层中药杂志,2002,16(2):325.
[4]Besedovsky Ho,Sorkin E,Felix D.Hypothalamic changes during the immune response.Eur J Immunol,1977(5):323-325.
[5]Basedovsky Ho,Sorkin E.Network of immuno-neuroendocrine interations.Chin Exp Immunol,1977,27(1):1.
[6]沈自尹.肾阳虚证的定位研究.中国中西结合杂志,1997,17(1):50-51.
[7]沈自尹.从肾本质研究到证本质的思考与实践.上海中医药杂志,2000,(4):6.
[8]陈英华,欧阳轶强,孙琪,等.肾阳虚证动物模型规范化研究中诊断指标选择的初步探讨.中国中医基础医学杂志,2003,9(10):26-30.
[9]郑里翔,刘晓庄,王莉,等.肾阳虚对大脑神经递质、胆碱酯酶的影响.新中医,2000,32(5):31-32.
[10]宋春风,尹桂山,李恩,等.补肾中药对肾阳虚大鼠下丘脑-垂体-肾上腺轴Fos蛋白表达的影响.中国中医基础医学杂志,2001,7(10):38-40.
[11]宋春风,郑师陵,吕佩源,等.补肾中药对肾阳虚大鼠下丘脑-垂体-肾上腺轴、血淋巴细胞Ca~(2+)和血清钙的影响.中国中医基础医学杂志,2002,8(5):34-36.
[12]宋春风,尹桂山,赵建宏.补肾中药对肾阳虚大鼠下丘脑-垂体-肾上腺轴cAMPKⅡ 的影响.中国中医基础医学杂志,2001,7(8):45-47.
[13]蒋淑君,王桂兰,许兰芝.糖皮质激素对HPAA的影响及仙灵脾的调整作用.滨州医学院学报,2004,27(2):88-90.
[14]宋春风,尹桂山,孙素,等.右归饮对肾阳虚大鼠下丘脑.垂体.肾上腺轴钙调素mRNA表达的影响.中国中医基础医学杂志,2001,7(3):20-22.
[15]钟历勇,沈自尹,蔡定芳,等.补肾健脾活血三类复方对下丘脑.垂体-肾上腺-胸腺轴及CRF基因表达的影响.中国中西医结合杂志,1997,17(1):39-41.
[16]高博,姚玉霞,张效云,等.肾阳虚大鼠下丘脑神经元型NOSmRNA表达及补肾药的调整作用.中国中医基础医学杂志,2001,7(8):23-24.
[17]高博,尹桂山.补肾药对肾阳虚大鼠下丘脑组织蛋白激酶活性的影响.中国中医基础医学杂志,2000,6(1):30-33.
[18]秦路平,张家庆.蛇床子香豆素对肾阳虚模型大鼠腺垂体-肾上腺皮质轴功能的影响.中国中西医结合杂志,1997,17(4):227-229.
[19]刘旭光,宋开源,余曙光,等.阴虚阳虚大鼠促肾上腺皮质激素及皮质酮昼夜节律的差异研究.四川中医,2002,20(1):6.
[20]宋春风,尹桂山,李恩,等.右归饮对肾阳虚大鼠下丘脑正中隆起室管膜细胞的影响.中国中医基础医学杂志,2001,7(1):19-22.
[21]宋春风,尹桂山,侯洁,等.补肾中药对肾阳虚大鼠垂体-肾上腺超微结构的影响.中医药研究,2001,17(2):41-42.
[22]李春生,张国玺,石体仁,等.山茱萸水溶性总提取物对肾阳虚动物模型生命质量和肾上腺组织的影响.中医杂志,2001,42(8):491.
[23]郭凯,徐蓉,俞伟,等.金匮肾气丸对肾阳虚动物模型影响的拆方研究.中医药学报,2003,31(1):20-21.
[24]宋春风,尹桂山,李恩,等.补肾益气中药对肾阳虚大鼠垂体.甲状腺超微结构的影响.中国中医基础医学杂志,1999,5(9):22-24.
[25]蒋淑君,崔存德,许兰芝.阳虚大鼠下丘脑.垂体.性腺轴钙调蛋白基因表达及补肾中药的调整作用.中国临床康复,2004,8(24):5056-5057.
[26]薛莎,汤学军.右归丸对肾阳虚动物模型血液微量元素含量的影响.中国中医药科技,2002,7(3):168-169.
[27]李春生,张国玺,石体仁,等.山茱萸水提取物对肾阳虚动物模型肝脏和睾丸影响的实验研究.中国中药杂志,2003,28(8):743-746.
[28]宋春风,马洪骏,吕佩源,等.补肾中药对肾阳虚大鼠垂体-睾丸超微结构的影响.中医药研究,2001,17(4):45-46.
[29]刘永琦,王文,虚证的免疫学本质.中国中医基础医学杂志,2003,9(5):7-10.
[30]冼国新,陈林香,戴馨仪,等.健脾补肾对正常小鼠和小鼠虚证模型一些免疫功能的实验研究.广州中医学院学报,1984,1(2):17-21.
[31]张建民,沈翔.“肾阳虚”小鼠免疫功能变化.浙江中医杂志,2002,19:260.
[32]马健,樊巧玲.阳虚模型小鼠腹腔巨噬细胞Ia抗原表达及乌头碱的作用.中国中西医结合杂志,1995,15(9):544-546.
[33]高梅.大黑蚂蚁水提液对阳虚动物模型免疫功能的影响.中国老年医学杂志,1999,19(1):49-50.
[34]李瑞荃,王明芳,潘学会,等.“益视明”对实验性肾阳虚大鼠红细胞免疫功能的影响.成都中医药大学学报,1997,20(1):41-42.
[35]施玉华.研究助阳药和滋阴药对阳虚动物模型的作用.上海中医药杂志,1981,(12):39.
[36]杜标炎,李道中,王培训.肾阳虚造型及补肾中药对大鼠免疫功能的影响.广州中医药大学学报,1996,13(1):37-39.
[37]雷娓娓,黄真炎,郑高飞,等.肾虚、脾虚造型动物免疫超微结构的比较研究.深圳中西医结合杂志,1999,9(2):14-15.
[38]王钰霞,陈魁敏.真武汤对阳虚小鼠作用的实验研究.中国实验方剂学杂志,2002,7(1):48-49.
[39]任丽民,刘承备.温脾汤治疗“肾阳虚”大鼠的实验研究.北京实验动物科学与管理,1994,11(3):34-36.
[40]黄厚才,彭蕴茹,沈明勤.金匮肾气丸对大鼠肾阳虚模型的影响.中国比较医学杂志,2004,14(3):155-157.
[41]王普京,严智强.氢化可的松动物模型的病理组织学观察及其中药的反证与治疗.中国中医基础医学杂志,1999,5(10):41-42.
[42]邝安堃,丁霆,陈家伦,等.阳虚(甲状腺功能减退)和阴虚(甲状腺功能亢进)病人血浆环核苷酸的对比.中医杂志,1979,7(7):21-24.
[43]何明大,杨锡兰,杨剑纲,等.保元口服液对阳虚小鼠血SOD、LPO及VitE的影响.湖南医科大学学报,1994,19(5):459-460.
[44]郑军,骆永珍.川产淫羊藿对“阳虚”模型动物血浆中分子物质与巯基含量的影响. 中国中药杂志,1995,2(4):238-239.
[45]薛莎,汤学军.微量元素测定对右归丸治疗家兔肾阳虚疗效的评价.湖北中医学院学报,2003,2(1):18-20.
[46]马威,薛莎,吴文莉.肾阳虚模型血液微量元素的聚类分析.数理医药学杂志,2000,13(2):127-128.
[47]秦路平,石汉平,王洪斌,等.蛇床子香豆素对肾阳虚模型大鼠学习记忆和神经肽的影响.第二军医大学学报,1997,18(2):147-149.
[48]司卉良,陈友香,侯安继,等.补肾汤对激素致更年期肾阳虚证大鼠卵巢功能的影响.中药药理与临床,2005,21(2):44-45.
[49]张婷,何嘉琳.育麟方对肾阳虚大鼠排卵功能的影响.现代中西医结合杂志,2005,14(16):2111-2113.
[50]刘蓬,卢标清,邱宝珊,等.不同补肾法对肾阳虚豚鼠模型听力的影响.现代康复,2001,5(11):58-59.
[51]邹世洁,陈小野.小鼠甲状腺机能减退肾阳虚模型的胃粘膜病理研究.吉林中医药,1997,(6):86-87.
[1]Nicholson JK,Wilson ID.Understanding global systems biology:Metabonomics and the continuum of metabolism.Nat Rev Drug Discov,2003,2(8):668-676.
[2]Brindle JT,Antti H,Holmes E,et al.Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H NMR-based metabonomics.NatMed,2002,8(12):1439-1444.
[3]Griffin JL,Bonney SA,Mann C,et al.An integrated reverse functional genomic and metabolic approach to understanding orotic acid-induced fatty liver.PhysiolGenomics,2004,17(2):140-149.
[4]Henry CM.The"metabonome" provides real-world information about drug toxicity,gene function.Chem Eng News,2002,80(48):66.
[5]Hector C.Metabonomic modeling of drug toxicity.Pharmacology &Therapeutics,2006,109(1-2):92-106.
[6]Garrod S,Humpfer E,Sprau LM,et al.High-resolution magic angle spinning 1H NMR spectroscopic studies on intact rat renal cortex and medulla.Magn Reson Med,1999,41(6):1108-1118.
[7]Garrod S,Humpher E,Connor SC,et al.High resolution 1H-NMR and magic angle spinning NMR spectroscopic investigation of the biochemical effects of 2-bromoethanamine in intact renal and hepatic tissue.Magn ResonMed,2001,45(5):781-790.
[8]Williams RE,Major H,Lock EA,et al.D-Serine-in-duced nephrotoxicity:a HPLC-TOF/MS-based metabonomics approach.Toxicology,2005,207(2):179-190.
[9]Wilson ID,Nicholson JK,Castro-Perez,et al.High resolution "Ultra performance" liquid chromatography coupled to TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies.J Proteome Res,2005,4(2):591-598.
[10]Lord G M,Tagore R,Cook T,et al.Nephropathy caused by Chinese herbs in the UK.Lancet,1999,354(9177):481-482.
[11]李晶,吴晓健,刘昌孝,等.代谢组学研究中数据处理新方法的应用.药学学报,2006,41(1):47-53.
[12]Ebbels T,Keun H,Beckonert O,et al.Toxicity classification from metabonomic data using a density superposition approach:"CLOUDS".Anal Chim Acta,2003,490(1-2):109-122.
[13]Shockcor JP,Holmes E.Metabonomics applications in toxicity screening and disease diagnosis.Curr Top Med Chem,2002,2(1):35.
[14]Wright SN.Comperison of aconitine-modified human heart(hH1) and rat skeletal(mu1)muscle Na+ channels:an important role for external Na+ ions.J Physiol.2002,538(Pt 3):759-771.
[15]Slim RM,Roberstson DG,Ajbassam M,et al.Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats.Toxicol Appl Res,2003,183(2):108.
[16]彭双清,廖艳,领贤忠.药物毒性作用机制的代谢组学.毒理学杂志,2005,19(3)增刊:175.
[17]Soga T,Baran R,Suematsu M,et al.Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption.J Biol Chem,2006,281(24):16768-16776.
[18]Yang J,Zhao X,Liu X,et al.High performance liquid chromatography-mass spectrometry for metabonomics:potential biomarkers for acute deterioration of liver function in chronic hepatitis B.Proteome Res,2006,5(3):554.
[19]刘昌孝.代谢组学的发展与药物研究开发.天津药学,2005,17(2):1-6.
[20]Ko RJ.Perspective on the adverse reactions from traditional Chinese medicines.J Chin Merl Assoc,2004,67(3):109.
[21]Liu CX.Metabonomics in modern research of traditional Chinese medicines.Chinese Traditional and Herb Drugs,2004,35(6):601.
[22]赵剑宇,颜贤忠,彭双清.关木通肾毒性的代谢组学研究.中草药,2006,37(5):725-730.
[23]Goodacre R,Vaidyanathan S,Dunn WB,et al.Metabolomics by numbers:acquiring and understanding global metabolite data.Trends Biotechnol,2004,22(5):245.
[24]Nielsen J,Oliver S.The next wave in metabolome analysis.Trends Biotechnol,2005,23(11):544.
[25]Thomas CE,Ganji G.Integration of genomic and metabonomic data in systems biology are we "there" yet?Curr Opin Drug Discov Devel,2006,9(1):92.
[26]Coen M,Lenz EM,Nicholson JK,et al.An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy.Chem Res Toxicol,2003,16(3):295-303.
[1]薛文礼.从中药的安全性谈中药的国际化.中医药信息,2005,2(22):6-7.
[2]周宜.从《内经》“有故无殒”思想看中药毒性研究.中国中医基础医学杂志.2007,13(5):342-343.
[3]王丽霞,陆丽珠.中药安全性探讨.药物不良反应杂志,1999,1(2):88-91.
[4]刘树民,李玉洁,罗明媚.中药毒性研究及思路探讨.世界科学技术—中医药现代化.2003,5(2):21-23.
[5]张立东.中药的有毒与无毒探析.中医药学刊,2006,24(10):1946-1947.
[6]陈学习,彭成.对附子毒性的再认识.辽宁中医药大学学报,2007,9(6):7-8.
[7]朱林平.附子毒性研究概况.江西中医药,2004,35(6):53-55.
[8]凌一揆.中药学.上海科学技术出版社,1985,108.
[9]邝安堃,吴裕,丁霆,等.某些助阳药对于大剂量皮质素所致耗竭现象的影响.中华内科杂志,1963,2:113-116.
[10]李勇枝.中医肾虚证研究进展.中国中医基础医学杂志,1996,2(4):56-60.
[11]钟历勇,沈自尹,蔡定芳,等.补肾健脾活血三类复方对下丘脑-垂体-肾上腺-胸腺轴及CRF基因表达的影响.中国中西医结合杂志,1997,17(1):39-41.
[12]陈奇.阴虚、阳虚动物模型和中药作用与评价.中药药理与临床,1991,7(5):47-48.
[13]张新民,段元丽,沈自尹,等.三类中药复方对侧脑室内注射IL-1大鼠下丘脑-垂体-肾上腺皮质轴反应状态的影响.中医杂志,2002,43(1):59-62.
[14]Chrousos GP.The hypothalamic-Pituitary-adrenal axis and immune-mediated inflammation.N Engl JMed,1995,332:1351-1362.
[15]Cho YM,Kim SY,Cho BY,et al.Dissociation between Plasma adrenoCORticotropin and serum CORtisol level during the early postoperative period after gastrectomy.Horm Res,2000,53:246-250.
[16]Nicholson JK,Connelly J,Lindon JC.,et al.Metabonomics:a platform for studying drug toxicity and gene function.Nat Rev Drug Diacov,2002,1(2):153-161.
[17]Zhang X,Wu H,Liao P,et al.NMR-based metabonomic study on the eubacute toxicity of ariatolochic acid in rats.Food Chemical Toxicology,2006,44:1006-1014.
[18]Coen M,Lenz EM,Nicholson JK,et al.An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR aspectroscopy.Chemical Research Toxicology,2003,16(3):295-303.
[19]Lindon JC.,Nicholson JK,HolmesE,et al.Contemporary issues in toxicology,the role of metabonomics in toxicology and its evaluation by the COMET project.Toxicol Appl Pharmacol,2003,187:1371.
[20]Ogiso H,Suzuki T,Taguchi R.Development of a reverse-phase liquid chromatography electrospray ionization mass spectrometry method for lipidomics,improving detection of phosphatidic acid and phosphatidylserine.Anal Biochem,2008,375(1):124-131.
[21]Yu K,Sheng G,Sheng J,et al.A metabonomic investigation on the biochemical Perturbation in liver failure Patients caused by hepatitis B virus.J Proteome Res,2007,6(7):2413-2419.
[22]Yang J,Zhao X,Liu X,et al.High Performance liquid chromatography-mass spectrometry for metabonomics:potential biomarkers for acute deterioration of liver function in chronic hepatitis.J Proteome Res,2006,5(3):554-561.
[23]Kaden J J,Dempfe CE,Sueselbeek T,et al.Time dependent in the plasma concentration of matrix met alloproteinase after acute myocardial infarction.Cardiology,2003,99(3):140-144.
[24]Chien CH,Yen MH,Liu HW,et al.Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cell:in comparison with oxidized LDL.Atherosclerosis,2000,151:481-491.
[25]Hiroharu K,Noriaki K,SusumuM,et al.Oxidized LDL modulates Bax/Bcl-2 through the lectinlike ox-LDL receptor-1 in vascular smooth muscle cell.Arterioscler Thromb Vase Biol,2001,21:955-960.
[26]Ren S,Shatadal S,Shen GX.Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells.Am J Physiol Endocrinol Metab,2000,278(4):656-662.
[27]周爱儒.生物化学.北京:人民卫生出版社,2000,123-130.
[25]Poutanen SM,Low DE,Henry B,et al.Identification of severe acute respiratory syndrome in Canada.N Engl J Med,2003,348(20):1995-2005.
[29]李春生,张国玺,石体仁,等.山茱萸水提取物对肾阳虚动物模型肝脏和睾丸影响的实验研究.中国中药杂志,2003,28(8):743-746.
[30]Shimizu Hiroshi.NUR study of aconitine poisoning.Wakan Iyaku Cakkaishi,1985,2(3):23.